FDA Awards Stealth BioTherapeutics Fast Track for MTP-131

Stealth BioTherapeutics has scooped up FDA fast track designation for its MTP-131 — also known as Bendavia — for the treatment of primary mitochondrial myopathy.

MTP-131 fights the disease by targeting the inner mitochondrial membrane.

The drug is currently in a Phase 1/2 trial with results expected midyear, the Newton, Mass.-based company says.